德国Merk对EGFR/MUC1 ADC的介绍中,强调了通过双靶点定位提高特异性降低副作用,同时协同结合增加肿瘤内化率增强毒素作用的设计思路。 图3 德国默克EGFR/MUC1 ADC(来源:公开资料) 阿斯利康的EGFR/cMet双抗ADCAZD9592,通过可切割Linker将抗体与TOP1i载荷AZ14170132偶联,相较于EGFR,AZD9592对cMet具有更高的亲和力(>15 ...
德国Merk对EGFR/MUC1 ADC的介绍中,强调了通过双靶点定位提高特异性降低副作用,同时协同结合增加肿瘤内化率增强毒素作用的设计思路。 图3 德国默克EGFR/MUC1 ADC(来源:公开资料) 阿斯利康的EGFR/cMet双抗ADCAZD9592,通过可切割Linker将抗体与TOP1i载荷AZ14170132偶联,相较于EGFR,AZD9592对cMet具有更高的亲和力(>15 ...
5、BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model 一种首创的靶向FOLR1和MUC1的双特异性ADC药物在FOLR1低水平的异种移植模型中展现出有希望的抗肿瘤活性 汇报者:C. Guo,百奥赛图医药 ■摘要号:LB129 Preclinical development of ...
今年的AACR会议上,百奥赛图带来了多款临床前双抗ADC的进展,包括靶向5T4 × MUC1的双抗ADC药物BCG016、PTK7 × EGFR双抗ADC药物BCG017和EGFR × HER3双抗ADC药物BCG019,它们在临床前都显示良好的抗肿瘤活性。 03小结 双抗ADC因融合了ADC和双抗的优点,有望克服ADC引起耐药等问题而备受关注,百利天恒的BL-B01...
Provided are immunoconjugates comprising bispecific anti-MUC 1/EGFR antibodies conjugated to hemiasterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.KNUEHL, CHRISTINE...
2、EGFR双抗ADC 双抗或双抗ADC药物的开发的根本目的在于增效、减毒,期望通过多通路作用增强疗效,以及提高对肿瘤靶向性减低外周副作用。针对像正常组织也有表达的EGFR靶点,双靶药物能够实现降低外周在靶毒性更为重要。 德国Merk对EGFR/MUC1 ADC的介绍中,强调了通过双靶点定位提高特异性降低副作用,同时协同结合增加肿瘤...
The present invention relates to a pharmaceutical composition comprising a bispecific anti-MUC1/EGFR antibody-drug conjugate (EGFR x MUC1 - Hemiasterlin bispecific antibody-drug conjugate (ADC)), a polyoxyethylene-polyoxypropylene block copolymer and a buffer, particularly a pharmaceutical preparation ...
bispecific antibodybreast cancersurfaceomeEGFRMUC1Breast cancer (BC) treatment has traditionally been challenging due to tumor heterogeneity. Bispecific antibodies (bsAbs) offer a promising approach for overcoming these challenges by targeting multiple specific epitopes. In the current study, we designed a...